A Phase 3 interventional study of Cytisinicline and Placebo in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Achieve Life Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.
Among the 22 studies testing cytisine in Smoking Cessation, this one is the 7th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 15th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health
Ages 18+
Maimónides Biomedical Research Institute of Córdoba
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 7 · Phase 4 3
First in 2016; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 792 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 202 across the 22 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Achieve Life Sciences is the lead sponsor of 31 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
10 studies in Smoking Cessation by Achieve Life Sciences: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Smoking Cessation by Achieve Life Sciences, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 3, and was the 7th registered.
Achieve Life Sciences’s Smoking Cessation studies by the year they started, since 2017.
1 of the studies testing cytisine in Smoking Cessation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06617312University of California, Los AngelesExamining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing cytisine in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Achieve Life Sciences’s 10 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One placebo tablet orally (PO) three times daily (TID) for 12 weeks plus behavioral support
Drug: Placebo · Behavioral: Behavioral support
One cytisinicline tablet PO TID for 6 weeks followed by one placebo tablet PO TID for 6 weeks plus behavioral support
Drug: Cytisinicline · Drug: Placebo · Behavioral: Behavioral support
One cytisinicline tablet PO TID for 12 weeks plus behavioral support
Drug: Cytisinicline · Behavioral: Behavioral support
film-coated oral tablets containing 3 mg cytisinicline
Also known as: Cytisine
film-coated oral tablets containing matched placebo
Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6
Smoking abstinence as verified by weekly expired carbon monoxide (CO) measurements ≤ 10 parts per million (ppm).
Time frame: Weeks 3 to 6
Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12
Smoking abstinence as verified by weekly expired CO measurements ≤ 10 ppm.
Time frame: Weeks 9 to 12
Percentage of Participants With Continuous Smoking Abstinence From Week 3 to Week 24
Smoking abstinence as verified by expired CO measurements ≤ 10 ppm. Measurements were weekly from Week 3 to Week 12 and monthly from Week 12 to Week 24.
Time frame: Week 3 to Week 24
Percentage of Participants With Continuous Smoking Abstinence From Week 9 to Week 24
Smoking abstinence as verified by expired CO measurements ≤ 10 ppm. Measurements were weekly from Week 9 to Week 12 and monthly from Week 12 to Week 24.
Time frame: Week 9 to Week 24
Percentage of Participants Taking Cytisinicline Who Are Relapse-Free at Week 24
Relapse is defined as participant reported resuming smoking or an expired CO measure ≥ 10 ppm. Relapse is defined as a participant having met one of the following: not being abstinent from Weeks 3 to 6; not being abstinent at the Week 12 visit; not being abstinent or not self-reporting abstinence during the Week 16 to Week 24 follow-up period. (During the follow-up period \[Weeks 16 to 24\], up to a total of 5 cigarettes could have been smoked.)
Time frame: Week 24
| Milestone | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support |
|---|---|---|---|
| Started | 265 | 263 | 264 |
| Completed | 209 | 207 | 212 |
| Not completed | 56 | 56 | 52 |
| Withdrew: Adverse event | 3 | 4 | 5 |
| Withdrew: Withdrawal by subject | 27 | 30 | 24 |
| Withdrew: Physician decision | 1 | 3 | 2 |
| Withdrew: Death | 0 | 1 | 3 |
| Withdrew: Lost to follow-up | 23 | 16 | 14 |
| Withdrew: Other, nor specified | 2 | 2 | 4 |
Smoking abstinence as verified by weekly expired carbon monoxide (CO) measurements ≤ 10 parts per million (ppm).
| percentage of participants | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support |
|---|---|---|
| Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6 | 6.0 | 14.8 |
Smoking abstinence as verified by weekly expired CO measurements ≤ 10 ppm.
| percentage of participants | Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support |
|---|---|---|
| Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12 | 9.4 | 30.3 |
Smoking abstinence as verified by expired CO measurements ≤ 10 ppm. Measurements were weekly from Week 3 to Week 12 and monthly from Week 12 to Week 24.
| percentage of participants | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support |
|---|---|---|
| Percentage of Participants With Continuous Smoking Abstinence From Week 3 to Week 24 | 1.1 | 6.8 |
Smoking abstinence as verified by expired CO measurements ≤ 10 ppm. Measurements were weekly from Week 9 to Week 12 and monthly from Week 12 to Week 24.
| percentage of participants | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Percentage of Participants With Continuous Smoking Abstinence From Week 9 to Week 24 | 4.2 | 20.5 |
Relapse is defined as participant reported resuming smoking or an expired CO measure ≥ 10 ppm. Relapse is defined as a participant having met one of the following: not being abstinent from Weeks 3 to 6; not being abstinent at the Week 12 visit; not being abstinent or not self-reporting abstinence during the Week 16 to Week 24 follow-up period. (During the follow-up period \[Weeks 16 to 24\], up to a total of 5 cigarettes could have been smoked.)
| percentage of participants | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support |
|---|---|---|
| Percentage of Participants Taking Cytisinicline Who Are Relapse-Free at Week 24 | 8.7 | 10.6 |
Collected over From signing of informed consent through Week 24. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Behavioral Support | 0/262 (0%) | 8/262 (3.1%) | 110/262 (42%) |
| 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 1/263 (0.4%) | 8/263 (3%) | 132/263 (50.2%) |
| 12-Week Cytisinicline + Behavioral Support | 3/260 (1.2%) | 8/260 (3.1%) | 137/260 (52.7%) |
| Event | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support |
|---|---|---|---|
| FatigueGeneral disorders | 0/262 | 0/263 | 1/260 |
| Groin abscessInfections and infestations | 0/262 | 0/263 | 1/260 |
| PneumoniaInfections and infestations | 1/262 | 0/263 | 1/260 |
| OverdoseInjury, poisoning and procedural complications | 0/262 | 0/263 | 1/260 |
| Stab woundInjury, poisoning and procedural complications | 0/262 | 0/263 | 1/260 |
| Haemorrhagic strokeNervous system disorders | 0/262 | 0/263 | 1/260 |
| ParanoiaPsychiatric disorders | 0/262 | 0/263 | 1/260 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/262 | 1/263 | 1/260 |
| Cholecystitis acuteHepatobiliary disorders | 1/262 | 0/263 | 0/260 |
| PyelonephritisInfections and infestations | 1/262 | 0/263 | 0/260 |
| Event | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support |
|---|---|---|---|
| InsomniaPsychiatric disorders | 20/262 | 29/263 | 32/260 |
| COVID-19Infections and infestations | 27/262 | 18/263 | 27/260 |
| NauseaGastrointestinal disorders | 19/262 | 26/263 | 19/260 |
| Abnormal dreamsPsychiatric disorders | 16/262 | 24/263 | 20/260 |
| HeadacheNervous system disorders | 18/262 | 21/263 | 22/260 |
| HypertensionVascular disorders | 13/262 | 7/263 | 8/260 |
| Upper respiratory tract infectionInfections and infestations | 9/262 | 11/263 | 12/260 |
| DiarrhoeaGastrointestinal disorders | 12/262 | 12/263 | 8/260 |
| Dry mouthGastrointestinal disorders | 6/262 | 12/263 | 6/260 |
| FatigueGeneral disorders | 3/262 | 7/263 | 11/260 |
| Age, Continuous(years) | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support | Total |
|---|---|---|---|---|
| Mean | 51 ± 11.4 | 52 ± 11.7 | 52 ± 12.3 | 52 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support | Total |
|---|---|---|---|---|
| Female | 146 | 142 | 151 | 439 |
| Male | 119 | 121 | 113 | 353 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support | Total |
|---|---|---|---|---|
| Hispanic or Latino | 17 | 15 | 13 | 45 |
| Not Hispanic or Latino | 248 | 248 | 251 | 747 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo + Behavioral Support | 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support | 12-Week Cytisinicline + Behavioral Support | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 0 | 5 |
| Asian | 0 | 2 | 2 | 4 |
| Black or African American | 51 | 38 | 50 | 139 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 2 |
| White | 210 | 216 | 205 | 631 |
| Other, Not Specified | 3 | 3 | 5 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in Mar 2023, 14 months.
Results were first posted in Jan 2026, 2 years 9 months after primary completion. A results delay was requested in Mar 2024.
Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytisine